+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: Serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection



Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: Serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection



Vaccine 13(11): 1023-1032



The protective efficacy of an alum-adsorbed, parenterally administered synthetic oligopeptide immunogen corresponding to antigenically common T-helper and neutralizing B-cell epitopes of the Chlamydia trachomatis major outer membrane protein was studied in a murine model of chlamydial genital tract infection. Mice produced high levels of anti-chlamydial serum IgG neutralizing antibodies following subcutaneous immunization with the alum-adsorbed oligopeptide. Lower but detectable levels of chlamydial specific IgG antibodies were found in vaginal washes. IgG1 was the predominant isotype present in sera and vaginal washes. Chlamydial-specific IgA was not present in either the sera or vaginal washes of immunized mice. Vaccinated and control mice were challenged intravaginally or intrauterinally with low, medium, or high doses of C. trachomatis serovar D challenge inocula. Protection was assessed by performing quantitative chlamydial cervico-vaginal cultures over the course of the infection period. There were no statistically significant differences between groups of immunized and control mice in either colonization, shedding, or duration of infection. These findings demonstrate that parenteral immunization with the oligopeptide (serum-neutralizing antibodies) is ineffective in preventing chlamydial genital tract infection. It is possible, since chlamydial infection is restricted to the genital tract mucosae, that a more accurate evaluation of the oligopeptide vaccine potential will require local rather than systemic immunization.

(PDF emailed within 0-6 h: $19.90)

Accession: 009265322

Download citation: RISBibTeXText

PMID: 8525685

DOI: 10.1016/0264-410x(95)00017-u


Related references

Sulfated polysaccharides and a synthetic sulfated polymer are potent inhibitors of Chlamydia trachomatis infectivity in vitro but lack protective efficacy in an in vivo murine model of chlamydial genital tract infection. Infection and Immunity 66(3): 1258-1260, 1998

Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infection and Immunity 63(12): 4704-4714, 1995

Chlamydial genital tract infections. Experimental infection of the primate genital tract with Chlamydia trachomatis. American Journal of Pathology 106(1): 132-135, 1982

Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. Journal of Infectious Diseases 212(6): 978-989, 2015

The significance of serum specific IgA antibody to Chlamydia trachomatis in the diagnosis and treatment of chlamydial infection in female genital tract. Nihon Sanka Fujinka Gakkai Zasshi 41(4): 479-486, 1989

Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen. Apmis 124(12): 1078-1086, 2016

The effect of adjuvants on the protective immunity induced by a whole cell vaccine against experimental chlamydia trachomatis ct genital tract infection gti. Abstracts of the General Meeting of the American Society for Microbiology 91: 120, 1991

Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis. Drugs of Today 45 Suppl B: 51-59, 2010

Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection. Infectious Diseases in Obstetrics and Gynecology 11(2): 81-87, 2003

Protective immunity following infection in experimental chlamydia trachomatis ct genital tract infection gti. Clinical Research 36(1): 146A, 1988

Cell-mediated immune responses in the genital tract and genital-associated lymph nodes to murine chlamydial genital infection. Abstracts of the General Meeting of the American Society for Microbiology 95(0): 277, 1995

The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sexually Transmitted Diseases 5(2): 73-77, 1978

Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infection and Immunity 67(6): 3019-3025, 1999

The potential protective role of the combination of IL-22 and TNF-α against genital tract Chlamydia trachomatis infection. Cytokine 73(1): 66-73, 2015

IFN- but not B-cells are important in protective immunity against a genital tract infection with Chlamydia trachomatis. Immunology Letters 56(Part-P1): 143-0, 1997